deferiprone has been researched along with Neoplasms in 4 studies
Deferiprone: A pyridone derivative and iron chelator that is used in the treatment of IRON OVERLOAD in patients with THALASSEMIA.
deferiprone : A member of the class of 4-pyridones that is pyridin-4(1H)-one substituted at positions 1 and 2 by methyl groups and at position 3 by a hydroxy group. A lipid-soluble iron-chelator used for treatment of thalassaemia.
Neoplasms: New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Iron mobilization from transferrin is one of the most important screening methods for the selection of chelators intended for clinical use in the treatment of iron overload in thalassemia and other conditions." | 8.83 | Iron mobilization from transferrin and non-transferrin-bound-iron by deferiprone. Implications in the treatment of thalassemia, anemia of chronic disease, cancer and other conditions. ( Kontoghiorghes, GJ, 2006) |
| "Iron mobilization from transferrin is one of the most important screening methods for the selection of chelators intended for clinical use in the treatment of iron overload in thalassemia and other conditions." | 4.83 | Iron mobilization from transferrin and non-transferrin-bound-iron by deferiprone. Implications in the treatment of thalassemia, anemia of chronic disease, cancer and other conditions. ( Kontoghiorghes, GJ, 2006) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (25.00) | 29.6817 |
| 2010's | 2 (50.00) | 24.3611 |
| 2020's | 1 (25.00) | 2.80 |
| Authors | Studies |
|---|---|
| Wu, Q | 1 |
| Young, B | 1 |
| Wang, Y | 1 |
| Davidoff, AM | 1 |
| Rankovic, Z | 1 |
| Yang, J | 1 |
| Khodaverdian, V | 1 |
| Tapadar, S | 1 |
| MacDonald, IA | 1 |
| Xu, Y | 1 |
| Ho, PY | 1 |
| Bridges, A | 1 |
| Rajpurohit, P | 1 |
| Sanghani, BA | 1 |
| Fan, Y | 1 |
| Thangaraju, M | 1 |
| Hathaway, NA | 1 |
| Oyelere, AK | 1 |
| Bedford, MR | 1 |
| Ford, SJ | 1 |
| Horniblow, RD | 1 |
| Iqbal, TH | 1 |
| Tselepis, C | 1 |
| Kontoghiorghes, GJ | 1 |
3 reviews available for deferiprone and Neoplasms
| Article | Year |
|---|---|
Recent Advances with KDM4 Inhibitors and Potential Applications.
Topics: Enzyme Inhibitors; Histone Demethylases; Humans; Jumonji Domain-Containing Histone Demethylases; Neo | 2022 |
Iron chelation in the treatment of cancer: a new role for deferasirox?
Topics: Animals; Antineoplastic Agents; Benzoates; Deferasirox; Deferiprone; Deferoxamine; Humans; Iron Chel | 2013 |
Iron mobilization from transferrin and non-transferrin-bound-iron by deferiprone. Implications in the treatment of thalassemia, anemia of chronic disease, cancer and other conditions.
Topics: Anemia; Chelation Therapy; Chronic Disease; Combined Modality Therapy; Deferiprone; Humans; Iron; Ir | 2006 |
1 other study available for deferiprone and Neoplasms
| Article | Year |
|---|---|
Deferiprone: Pan-selective Histone Lysine Demethylase Inhibition Activity and Structure Activity Relationship Study.
Topics: Animals; Catalytic Domain; Cell Line, Tumor; Deferiprone; DNA Methylation; Enzyme Assays; Enzyme Inh | 2019 |